This company has been acquired
LogicBio Therapeutics Crecimiento futuro
Future controles de criterios 0/6
Información clave
n/a
Tasa de crecimiento de los beneficios
-1.2%
Tasa de crecimiento del BPA
Crecimiento de los beneficios de Biotechs | 24.8% |
Tasa de crecimiento de los ingresos | -132.5% |
Rentabilidad financiera futura | n/a |
Cobertura de analistas | Low |
Última actualización | n/a |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
LogicBio jumps 648% on buyout deal with AstraZeneca unit Alexion
Oct 03Bullish: Analysts Just Made A Notable Upgrade To Their LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Forecasts
Aug 20LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Just Reported Second-Quarter Earnings And Analysts Are Lifting Their Estimates
Aug 18LogicBio GAAP EPS of -$0.15, revenue of $3.2M
Aug 15Is LogicBio Therapeutics (NASDAQ:LOGC) Weighed On By Its Debt Load?
Jan 11Does LogicBio Therapeutics (NASDAQ:LOGC) Have A Healthy Balance Sheet?
Aug 18LogicBio EPS misses by $0.06, beats on revenue
May 10LogicBio announces agreements with CANbridge Pharma and Daiichi Sankyo
Apr 27Is LogicBio Therapeutics (NASDAQ:LOGC) Using Debt Sensibly?
Apr 12Is LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Popular Amongst Insiders?
Mar 08The LogicBio Therapeutics (NASDAQ:LOGC) Share Price Has Gained 12% And Shareholders Are Hoping For More
Jan 15LogicBio extends collaboration with Children's Medical Research Institute
Jan 07LogicBio Therapeutics names new CFO
Dec 22Looking In On LogicBio
Nov 17LogicBio reports Q3 results
Nov 09Previsiones de crecimiento de beneficios e ingresos
Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
---|---|---|---|---|---|
12/31/2023 | N/A | N/A | -28 | N/A | 1 |
12/31/2022 | 10 | N/A | -27 | N/A | 2 |
9/30/2022 | 11 | -27 | -25 | -25 | N/A |
6/30/2022 | 10 | -31 | -29 | -28 | N/A |
3/31/2022 | 8 | -36 | -22 | -21 | N/A |
12/31/2021 | 5 | -40 | -20 | -19 | N/A |
9/30/2021 | 4 | -38 | -22 | -21 | N/A |
6/30/2021 | 3 | -36 | -17 | -17 | N/A |
3/31/2021 | 3 | -33 | -30 | -29 | N/A |
12/31/2020 | 3 | -33 | -29 | -29 | N/A |
9/30/2020 | 3 | -37 | -34 | -33 | N/A |
6/30/2020 | 2 | -40 | -39 | -38 | N/A |
3/31/2020 | 1 | -42 | -39 | -38 | N/A |
12/31/2019 | N/A | -40 | -40 | -39 | N/A |
9/30/2019 | N/A | -32 | -33 | -32 | N/A |
6/30/2019 | N/A | -29 | -27 | -26 | N/A |
3/31/2019 | N/A | -23 | -21 | -20 | N/A |
12/31/2018 | N/A | -18 | -16 | -15 | N/A |
9/30/2018 | N/A | -18 | -14 | -13 | N/A |
6/30/2018 | N/A | -11 | -11 | -11 | N/A |
3/31/2018 | N/A | -9 | -8 | -8 | N/A |
12/31/2017 | N/A | -8 | -6 | -6 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: Insufficient data to determine if LOGC's forecast earnings growth is above the savings rate (2%).
Beneficios vs. Mercado: Insufficient data to determine if LOGC's earnings are forecast to grow faster than the US market
Beneficios de alto crecimiento: Insufficient data to determine if LOGC's earnings are expected to grow significantly over the next 3 years.
Ingresos vs. Mercado: LOGC's revenue is expected to decline over the next 3 years (-132.5% per year).
Ingresos de alto crecimiento: LOGC's revenue is forecast to decline over the next 3 years (-132.5% per year).
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Insufficient data to determine if LOGC's Return on Equity is forecast to be high in 3 years time